Losartan Potassium Tablet
Product Images NDC 70010-742

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 70010-742). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Granules Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100-mg-30s (100 mg 30s)

Losartan Potassium Tablets, USP 100 mg oral tablets label shows a package of 30 tablets. It is manufactured by Granules India Limited in India and distributed by Granules Pharmaceuticals Inc., Chantilly, VA. The label includes storage instructions, dosage reference, and a website for patient information.*

FDA Label Image

25-mg-30s (25 mg 30s)

Losartan Potassium Tablets, USP, 25 mg oral tablets in a package of 30 tablets. Label includes NDC 70010-741-03 and mentions the product is manufactured by Granules India Limited, Hyderabad, India, and distributed by Granules Pharmaceuticals Inc., Chantilly, VA. The label states storage instructions, dosage reference, and patient information availability.*

FDA Label Image

50-mg-30s (50 mg 30s)

Losartan Potassium Tablets USP 50 mg oral tablets label from Granules Pharmaceuticals Inc. The label indicates the product contains 30 tablets and includes storage instructions, manufacturer details (Granules India Limited, Hyderabad, India), and distributor information (Granules Pharmaceuticals Inc., Chantilly, VA). The label also mentions patient information is provided separately and includes barcodes.*

FDA Label Image

Fig-1 (Fig 1)

A line graph comparing the percentage of patients with primary endpoint events over study months for Atenolol and Losartan Potassium. The x-axis represents the study month up to 66 months, and the y-axis shows the percentage of patients with primary endpoint events up to 16%. The graph includes an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Fig-2 (Fig 2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 study months between Atenolol (dashed line) and Losartan potassium (solid line). The graph shows a lower percentage for Losartan potassium, with an adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Fig-3 (Fig 3)

A forest plot comparing Losartan Potassium and Atenolol across various patient subgroups, including overall results, age, gender, race, isolated systolic hypertension, diabetes, and history of cardiovascular disease. The plot shows hazard ratios with 95% confidence intervals for primary composite and stroke (fatal/non-fatal) outcomes, visually indicating which treatment is favored in each category.*

FDA Label Image

Losartan-figure4-jpg (Losartan Figure4 Jpg)

A line graph showing the percentage of patients with an event over 48 months, comparing Losartan potassium to placebo. The graph indicates a 16.1% risk reduction with Losartan potassium, with a p-value of 0.022. The solid line represents Losartan potassium and the dotted line represents placebo.*

FDA Label Image

Losartan-structure-jpg (Losartan Structure Jpg)

Chemical structure diagram of Losartan Potassium, showing its molecular arrangement including rings, chlorine atom, potassium ion, and other chemical groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.